AURINIA PHARMACEUTICALS INC (AUPH) Stock Price, Quote, News and Overview
NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD
AUPH Quote, Performance and Key Statistics
7.89
+0.23 (+3%)
The current stock price of AUPH is 7.89 USD. In the past month the price decreased by -7.5%. In the past year, price increased by 60.69%.
AUPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About AUPH
Company Profile
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The firm contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. The company sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Company Info
AURINIA PHARMACEUTICALS INC
#140, 14315 - 118 Avenue
Edmonton ALBERTA V8Z 7X8 CA
CEO: Peter Greenleaf
Employees: 300
Company Website: https://www.auriniapharma.com
Investor Relations: https://ir.auriniapharma.com
Phone: 12507442487
AURINIA PHARMACEUTICALS INC / AUPH FAQ
What is the stock price of AURINIA PHARMACEUTICALS INC today?
The current stock price of AUPH is 7.89 USD. The price increased by 3% in the last trading session.
What is the ticker symbol for AURINIA PHARMACEUTICALS INC stock?
The exchange symbol of AURINIA PHARMACEUTICALS INC is AUPH and it is listed on the Nasdaq exchange.
On which exchange is AUPH stock listed?
AUPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AURINIA PHARMACEUTICALS INC stock?
13 analysts have analysed AUPH and the average price target is 10.17 USD. This implies a price increase of 28.95% is expected in the next year compared to the current price of 7.89. Check the AURINIA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AURINIA PHARMACEUTICALS INC worth?
AURINIA PHARMACEUTICALS INC (AUPH) has a market capitalization of 1.08B USD. This makes AUPH a Small Cap stock.
How many employees does AURINIA PHARMACEUTICALS INC have?
AURINIA PHARMACEUTICALS INC (AUPH) currently has 300 employees.
What are the support and resistance levels for AURINIA PHARMACEUTICALS INC (AUPH) stock?
AURINIA PHARMACEUTICALS INC (AUPH) has a support level at 7.4 and a resistance level at 7.96. Check the full technical report for a detailed analysis of AUPH support and resistance levels.
Is AURINIA PHARMACEUTICALS INC (AUPH) expected to grow?
The Revenue of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 9.41% in the next year. Check the estimates tab for more information on the AUPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AURINIA PHARMACEUTICALS INC (AUPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AUPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AUPH, evaluating the profitability, health, valuation and growth aspects
- AURINIA PHARMACEUTICALS INC (AUPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AURINIA PHARMACEUTICALS INC (AUPH) Sales and EPS estimates to see what analysts future expectations are.
- AURINIA PHARMACEUTICALS INC (AUPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AURINIA PHARMACEUTICALS INC (AUPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- AURINIA PHARMACEUTICALS INC (AUPH) Stock Chart to make your own analysis
- AURINIA PHARMACEUTICALS INC (AUPH) Latest news and press-releases to stay up to date.
Does AURINIA PHARMACEUTICALS INC (AUPH) stock pay dividends?
AUPH does not pay a dividend.
When does AURINIA PHARMACEUTICALS INC (AUPH) report earnings?
AURINIA PHARMACEUTICALS INC (AUPH) will report earnings on 2025-05-01.
What is the Price/Earnings (PE) ratio of AURINIA PHARMACEUTICALS INC (AUPH)?
The PE ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 87.67. This is based on the reported non-GAAP earnings per share of 0.09 and the current share price of 7.89 USD. Check the full fundamental report for a full analysis of the valuation metrics for AUPH.
What is the Short Interest ratio of AURINIA PHARMACEUTICALS INC (AUPH) stock?
The outstanding short interest for AURINIA PHARMACEUTICALS INC (AUPH) is 9.12% of its float. Check the ownership tab for more information on the AUPH short interest.
AUPH Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AUPH. When comparing the yearly performance of all stocks, AUPH is one of the better performing stocks in the market, outperforming 94.65% of all stocks.
AUPH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AUPH. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
AUPH Financial Highlights
Over the last trailing twelve months AUPH reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 116.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.45% | ||
| ROA | 1.04% | ||
| ROE | 1.52% | ||
| Debt/Equity | 0.16 |
AUPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to AUPH. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 405.47% and a revenue growth 9.41% for AUPH